mesothelioma
Oncology · 2005–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab and ipilimumab First-line treatment of patients with unresectable malignant pleural mesothelioma. | Jul 2024 | Noted | input received Lung Foundation |
| pemetrexed Patients with malignant pleural mesothelioma and patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell… | Mar 2023 | Recommended with restriction | input received Lung Foundation Australia |
| nivolumab plus ipilimumab First-line treatment of unresectable malignant pleural mesothelioma (MPM). The PBAC's recommendation allows use in first- and second-line treatment settings… | Mar 2021 | Recommended with restriction | 5 individuals Asbestos Victims Association · Asbestos Council · Asbestos Diseases Research Institute · Lung Foundation Australia · Asbestos Diseases Society of Australia · Rare Cancers Australia · Medical Oncology Group |
| pemetrexed Treatment of patients with locally advanced or metastatic non-small cell lung cancer (after prior platinum-based chemotherapy) and malignant pleural… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pemetrexed Additional 1 g strength for treatment of patients with malignant pleural mesothelioma in combination with cisplatin, and locally advanced or metastatic… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pemetrexed disodium Treatment of patients with malignant pleural mesothelioma in combination with cisplatin. | Nov 2007 | Recommended with restriction | no section in document |
| pemetrexed disodium Treatment of patients with malignant pleural mesothelioma in combination with cisplatin. | Nov 2007 | Recommended with restriction | no section in document |
| pemetrexed disodium Treatment of patients with malignant pleural mesothelioma in combination with cisplatin. | Nov 2005 | Recommended | no section in document |
| pemetrexed disodium Treatment of patients with malignant pleural mesothelioma in combination with cisplatin. | Nov 2005 | Recommended | no section in document |
Who spoke
Lung Foundation Australia · Lung Cancer Foundation Australia · Asbestos Victims Association · Asbestos Council · Asbestos Diseases Research Institute · Asbestos Diseases Society of Australia · Rare Cancers Australia · Medical Oncology Group · Lung Foundation
What the PBS pays
$199M in government benefit over 2024–25, across 11,929 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nivolumab and ipilimumab | $199M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| pembrolizumabPembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) | TA1125 | terminated | 2026-01 |
| nivolumabNivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | recommended restricted | 2022-08 |
| pemetrexedPemetrexed for the treatment of malignant pleural mesothelioma | TA135 | recommended restricted | 2008-01 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.